Enter your Email Address


Useful Links

Know What The Insiders Are Doing!
Stock Trading Software

More Links




[Most Recent Quotes from www.kitco.com]

[Most Recent Quotes from www.kitco.com]




GenVec’s TNFerade Nears NDA Status (NASDAQ:GNVC)

Michael Vlaicu (September 9th, 2009) Writes:

GenVec, Inc.

(Public, NASDAQ:GNVC)

StocksHaven Investments profiles a clinical stage biopharmaceutical company developing gene-based therapeutic drugs and vaccines. Its lead product candidate, TNFerade biologic (TNFerade), is being developed for use in the treatment of cancer, and is currently undergoing Phase III trials which are expected to be completed by Q1 2010. In addition to its therapeutic product development programs, GenVec is working with collaborators to develop new applications for its technology through its vaccine development programs. The Company is developing a vaccine in animal health against foot-and-mouth disease and preventative vaccines for malaria, human immunodeficiency virus (HIV), respiratory syncytial virus, and Herpes Simplex Virus Type 2 (HSV-2). Surrounded by cash infusions through grants, mutual and institutional investors, multi-purpose products with billion dollar market potential, and an already flowing revenue stream – GenVec is one company you shouldn’t pass by.

About

Genvec

...
Tags for this Post:
adenovector delivery, adenovector delivery technology, adenovector technology, adenovector vaccine candidate, adenovirus, Agricultural Research Service, Allergy, America, Analyst, and Lead Investment Analyst, antibodies, Antigenics Inc., Apple Inc, Associate Professor, balance disorders, bank of america corp, Barclays, Biotechnology, California, cancer, Cancer Research, Cancers, care for patients with balance disorders, ceo, Chemotherapy, clinical disease, Dendreon Corporation;, director, Douglas J. Swirsky, esophageal cancer, Executive Vice President, Executive Vice President of Research and Development, Fda, fibrosis;, Food Supply, foot-and-mouth disease, founder, Gaithersburg;, gene expression, gene therapy, GenVec Inc., Head And Neck Cancer, hearing loss;, HIV, Infectious Diseases, Laszlo Zsak, lead therapeutic product candidate, locally advanced pancreatic cancer, Major, Malaria, manager, Marvin Grubman, Maryland, meat products, Michael Vlaicu;, multi-purpose products, National Institute of Allergy, National Institute of Allergy and Infectious Diseases of the National Institutes of Health, Naval Medical Research Center, necrosis, Oncologix Inc., Pancreatic Cancer, parasitic disease, Patrick Swazy, Paul H. Fischer, Pfizer Inc, Ph.D., Pharmaceutical, Plum Island Animal Disease Center, president and chief executive officer, Professor of Human Oncology, Q1, radiation, rectal cancer, Researchers of the Livestock Sciences, Reuters, Royce Micro, SAIC-Frederick Inc., San Francisco, second-generation vaccine candidate, Spartan Micro, stage biopharmaceutical;, Steve Jobs, Stocks to Watch, targeted radiation therapy, therapy for locally advanced pancreatic cancer, TherAtoh, TNFerade;, TNFerade™;, transcriptional start site, treatment of inoperable, treatment of locally advanced pancreatic cancer;, treatment of pancreatic cancer, treatment of various cancers;, tumor, tumors, U.S. Department of Agriculture, U.S. Food and Drug Administration, United Kingdom, United States, University of California at San Francisco, University of California Irvine Comprehensive Digestive Disease Center, University of Denver, University Of Wisconsin, USD, USDA, vaccine candidate, Vaccine Research Center, Vaccine Research Center/National Institute, Vaccines, Vice President and Chief Financial Officer, Vice President of Research and Development, Wisconsin, Yahoo, yale, Yale University School of Medicine

Beacon Equity Research Featured Company: XOMA Ltd. (XOMA)

QualityStocks (August 7th, 2009) Writes:

XOMA is a biopharmaceutical company that discovers, develops and manufactures therapeutic antibodies. These antibodies and other agents are developed in order to treat inflammatory, autoimmune, infections and oncological diseases.

The company has a premier antibody discovery and development platform that incorporates leading antibody phage display libraries and XOMA’s proprietary Human Engineering(tm) and Bacterial Cell Expression (BCE) and manufacturing technologies.

Partnering with companies, such as Novartis AG, Schering-Plough Research Institute and Takeda Pharmaceutical Company Limited, enables XOMA to develop additional antibodies with multi-indication potential. Partnering not only allows XOMA access to new drug targets, but will add substantially to the generation of more revenue for the company.

XOMA was awarded a $65 Million multiple year contract from the National Institute of Allergy and infectious Diseases (NIAII). This contract will support XOMA’ s ongoing development of drug candidates towards clinical trials in the treatment of botulism poisoning, which could be

...

Newsletter

No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.